The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways Summary GBI Research, the leading business intelligence provider, has released its latest research “The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways”. The report provides insights on the biosimilars market revenues and growth until 2015. Further, the distribution of revenues across key geographies such as the US, the top five countries in Europe and Japan are provided in the report. The report discusses the latest developments in the regulatory landscape and the evolving biosimilars approval pathways in Europe, the US and Japan. In-depth analysis into the individual segments of biosimilars market, their market forecasts and potential are also provided. The study analyzes the competitive landscape including benchmarking of the leading companies in the biosimilars market. Finally, a key trends analysis of mergers and acquisitions and licensing agreements involving biosimilars, is also provided. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope The scope of this report includes: - Analysis on the regulations for biosimilars market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan
- Market forecasts and potential for the biosimilars market from 2008 to 2015. The key biologics classes included are human growth hormones, granulocyte colony stimulating factors, insulins, interferons and erythropoietins
- Market characterization data for biosimilars including market size, market share and market potential
- Key drivers and restraints that have a significant impact on the market
- Competitive landscape of global biosimilars market including benchmarking of the leading companies. The key companies discussed in this report are Teva, Sandoz, Hospira Inc, STADA Arzneimittel AG, Ratiopharm, Dr.Reddy’s Laboratories and Biocon Ltd
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global biosimilars market
Reasons to buy The report will enable business development and marketing executives strategizing their product launches to - Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the US, Europe and Japan
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps
- Develop key strategic initiatives by studying the key strategies of top competitors
- Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety
This Report is NOT a downloadable item but will be delivered via
email within 24 h (working days only)
|
